RSS Feeds
Gatifloxacin-Induced Hyperglycemia
- Marc R. Happe, DO;
- Brian P. Mulhall, MD;
- Corinne L. Maydonovitch, BS; and
- Kent C. Holtzmuller, MD
- From Walter Reed Army Medical Center, Washington, DC 20307.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Fourth-generation fluoroquinolones are broad-spectrum antibiotics frequently used to treat a wide variety of infections. Gatifloxacin (Tequin, Bristol-Myers Squibb, Princeton, New Jersey) is one of the newest and most effective quinolones (1). A small number of cases in the literature have …
